You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

632 Results
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer
Sep 2023
Guidelines and Advice
Status: Current
ID: GL 1-25
Version: N/A
Mar 2023
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix
Jun 2023
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Treated MSI-H/dMMR Advanced Endometrial Cancer
Jul 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Pegaspargase (Outpatient) - Adult Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma Mixed or Biphenotypic Leukemia
Apr 2022
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Feb 2023
Drug
Other Name(s): Polivy™
Dec 2022

Pages